Last November, Michael Bublé and his wife announced that their three-year-old son Noah had been diagnosed with liver cancer for which he had started receiving chemotherapy. A tragic news that forced both of them to put aside their careers to dedicate themselves exclusively to the care of their child.
Fortunately, the news is now much more optimistic and hopeful. On Monday, his mother Luisiana Lopilato, spoke for the first time on the subject at a press conference in which confirmed that the little one has overcome cancer. "Thank God my son is fine"said the Argentine actress.
After a four-month chemotherapy treatment in the United States, the family moved home in Buenos Aires. There, the actress has given a press conference in which she recognizes that her faith and her family helped her overcome the toughest moments.
I want to thank people for the support, for the chains of prayers they made, for love and I want them to know that everything came. That helped us a lot to get ahead. I want to share with you that thank God my son is fine.
Of course, it is a long process. Noah has to continue with controls, but we are very happy. We really want to think about the future, to see our children grow up.
The rapid detection of the tumor was key to the success of the treatment. In November he began to undergo the two phases of chemotherapy to treat the disease. In February he was operated to remove the tumor and confirmed that it had not spread to other organs.
The child should follow a drug treatment and undergo a series of short-term checkups.
The couple also has another fifteen-month-old child, Elias.
A hopeful news
The diagnosis of a child's cancer is one of the most devastating news that parents can receive. Every year, they are diagnosed in the world more than 150,000 new cases in children (in Spain 1,400 new cases in children under 18) whose lives become a struggle to survive.
Liver cancer is not one of the most common types of cancer in childhood. They are: leukemia (approximately 25%), central nervous system tumors (approx. 20%), non-Hodgkin lymphoma (approx. 6%), Hodgkin's disease (5%) and Wilms tumor in the kidney (5%), Ewing's sarcoma and thyroid cancer.
A hopeful fact is that according to the Spanish Society of Pediatric Hemato-Oncology, the 5-year survival rate from 0 to 14 years reaches almost 80 percent. However, it strives to get that rate closer and closer to one hundred percent.
